Article: Center for Inherited Disease Research (CIDR) to Use Illumina Whole-Genome Genotyping Solutions to Support Study for Finland-United States Type 2 Diabetes Collaboration.

SAN DIEGO -- Data from Illumina BeadChips and Infinium(TM) Assay Reagents Will Help Identify Genetic Variants that Predispose Individuals to Type 2 Diabetes

Illumina, Inc. (NASDAQ:ILMN) announced today that it is partnering with the Center for Inherited Disease Research (CIDR) to use the Sentrix(R) HumanHap300 BeadChip and Infinium(TM) Assay for a pilot study of Type 2 Diabetes. One goal of this study is to evaluate the Illumina technology for possible adoption as the standard platform for CIDR's genome-wide association service to be offered to the scientific community in the spring of 2006.

CIDR is working with Illumina to genotype over 2500 ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!